Humacyte logo

HumacyteNASDAQ: HUMA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

01 December 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$634.95 M
-46%vs. 3y high
68%vs. sector
-vs. 3y high
-vs. sector
-22.45
-154%vs. 3y high
2%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 5 min ago
$5.32+$0.19(+3.71%)

Dividend

No data over the past 3 years
$420.00 K$420.00 K

Analysts recommendations

Institutional Ownership

HUMA Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humacyte, Inc. - HUMA
accesswire.com01 November 2024 Sentiment: -

NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ:HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
accesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / October 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ:HUMA). Investors who purchased Humacyte securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HUMA.

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
zacks.com31 October 2024 Sentiment: NEGATIVE

Humacyte, Inc. (HUMA) closed at $5.05 in the latest trading session, marking a -1.94% move from the prior day.

Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman
globenewswire.com31 October 2024 Sentiment: NEGATIVE

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- On October 17, 2024, the U.S. Federal Food & Drug Administration (“FDA”) published its April 5, 2024 report addressed to Humacyte's Chief Operating Officer (Heather Prichard) detailing problems with Humacyte's facilities. The FDA's April 5, 2024 report submitted to Prichard appears to potentially contradict her assurances to investors at an earnings call on May 12, 2024 in response to analyst questions.

Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
globenewswire.com28 October 2024 Sentiment: NEGATIVE

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ: HUMA), a biotechnology company focused on developing acellular tissue engineered vessels, has faced significant setbacks in recent months due to regulatory scrutiny from the U.S. Food and Drug Administration (FDA). The company's stock price has plummeted following disclosures of FDA violations at its manufacturing facility and delays in the approval process for its flagship product.

Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024
globenewswire.com28 October 2024 Sentiment: POSITIVE

– ATEV™ demonstrated superiority at six and 12 months (co-primary endpoints) compared to autogenous fistula, the current standard of care for hemodialysis access –

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why
zacks.com24 October 2024 Sentiment: POSITIVE

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $5.82, indicating a +1.75% shift from the previous trading day.

Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman
globenewswire.com24 October 2024 Sentiment: NEGATIVE

SAN FRANCISCO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- On October 17, 2024, the U.S. Federal Food & Drug Administration (“FDA”) published its April 5, 2024 report addressed to Humacyte's Chief Operating Officer (Heather Prichard) detailing problems with Humacyte's facilities. The FDA's April 5, 2024 report submitted to Prichard appears to potentially contradict her assurances to investors at an earnings call on May 12, 2024 in response to analyst questions.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
businesswire.com23 October 2024 Sentiment: NEGATIVE

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Humacyte investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
businesswire.com22 October 2024 Sentiment: NEGATIVE

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 9, 2024, after market hours, Humacyte disclosed that the FDA needed “additional time to complete its review of its Biologic License Application (BLA) for the acellular.

  • 1(current)
  • 2
  • 3

What type of business is Humacyte?

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

What sector is Humacyte in?

Humacyte is in the Healthcare sector

What industry is Humacyte in?

Humacyte is in the Biotechnology industry

What country is Humacyte from?

Humacyte is headquartered in United States

When did Humacyte go public?

Humacyte initial public offering (IPO) was on 01 December 2020

What is Humacyte website?

https://www.humacyte.com

Is Humacyte in the S&P 500?

No, Humacyte is not included in the S&P 500 index

Is Humacyte in the NASDAQ 100?

No, Humacyte is not included in the NASDAQ 100 index

Is Humacyte in the Dow Jones?

No, Humacyte is not included in the Dow Jones index

When was Humacyte the previous earnings report?

No data

When does Humacyte earnings report?

The next expected earnings date for Humacyte is 08 November 2024